cobas HPV for use on the cobas 6800/8800 Systems
Roche Molecular Systems, Inc. · Decision date Apr 3, 2020
What did the FDA approve?
FDA approved the original PMA for Roche Molecular Systems' cobas HPV test on the cobas 6800/8800 Systems. The device is a qualitative in vitro test for detecting Human Papillomavirus in clinician-collected cervical specimens placed in ThinPrep Pap Test PreservCyt Solution. It detects high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
The stated indications cover routine cervical cancer screening per professional medical guidelines, including ASC-US cytology triage, co-testing with cytology, and HPV primary screening to assess cervical precancer and cancer risk. The source statement reports these intended uses but does not itself provide independent proof of safety or clinical effectiveness. No supplement type or reason is recorded.
FDA approval order statement
Approval for the cobas HPV for use on the cobas 6800/8800 Systems. cobas HPV for use on the cobas 6800/8800 Systems (cobas HPV) is a qualitative in vitro test for the detection of Human Papillomavirus in clinician-collected cervical specimens using an endocervical brush/spatula or broom and placed in the ThinPrep Pap Test PreservCyt Solution. This test detects the high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. cobas HPV is indicated for use for routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (or adjunctive screen) with cytology, and HPV primary screening of women to assess the risk for cervical precancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Microbiology
- Decision date
- Apr 3, 2020
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P190028
- Regulatory pathway
- Premarket approval application
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MAQ
- Decision code
- APPR
- Decision date
- Apr 3, 2020
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MAQ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P190028 received
Application receipt date recorded by FDA.
P190028 · FDA decision
APPR
P190028/S026 · Related supplement
cobas HPV
Timeline entries are records held by MedtechLedger for P190028. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190028
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HPVP190028/S026 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code MAQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HPVP100020/S066 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Alinity m HR HPVP230003/S019 | Abbott Molecular, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Alinity m HR HPVP230003 | Abbott Molecular, Inc. | PMA approval | Nov 1, 2023 | FDA |
COBAS HPV TESTP100020 | Roche Molecular Systems, Inc. | PMA approval | Apr 19, 2011 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- roche.com
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P190028
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



